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Background: The prognostic value of circulating tumor cells (CTCs) in colorectal cancer (CRC) patients and their
value in predicting tumor response to chemotherapy are controversial. The aim of this meta-analysis was to assess
the prognostic and predictive value of CTCs in CRC patients treated with chemotherapy.
Methods: A comprehensive literature search for relevant studies was conducted in PubMed, Embase, the Cochrane
Database, the Science Citation Index and the Ovid Database, and the reference lists of relevant studies were also
perused for other relevant studies (up to April, 2014). Using the random-effects model in Stata software, version
12.0, the meta-analysis was performed using odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence
intervals (CIs) as effect measures. Subgroup and sensitivity analyses were also performed.
Results: Thirteen eligible studies were included. Our meta-analysis indicated that the disease control rate was significantly
higher in CRC patients with CTC-low compared with CTC-high (RR = 1.354, 95% CI [1.002–1.830], p = 0.048). CRC
patients in the CTC-high group were significantly associated with poor progression-free survival (PFS; HR = 2.500, 95%
CI [1.746–3.580], p < 0.001) and poor overall survival (OS; HR = 2.856, 95% CI [1.959–4.164], p < 0.001). Patients who
converted from CTC-low to CTC-high or who were persistently CTC-high had a worse disease progression (OR = 27.088,
95% CI [4.960–147.919], p < 0.001), PFS (HR = 2.095, 95% CI [1.105–3.969], p = 0.023) and OS (HR = 3.604,
95% CI [2.096–6.197], p < 0.001) than patients who converted from CTC-high to CTC-low.
Conclusions: Our meta-analysis indicates that CTCs are associated with prognosis in CRC patients treated with
chemotherapy. Moreover, CTCs could provide additional prognostic information to tumor radiographic imaging and
might be used as a surrogate and novel predictive marker for the response to chemotherapy.
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Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and the second in females
worldwide [1]. Approximately 50% of CRC patients will
develop subsequent metastasis or recurrence, regardless
of curative resection. Despite these outcomes, standard
combined chemotherapy has been successfully used to
increase the cure rate [2,3]. In recent decades, significant* Correspondence: josieon826@sina.cn
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unless otherwise stated.improvements have been made in the response rate,
disease control rate, progression-free survival (PFS) and
overall survival (OS) of CRC patients [4,5].
However, despite the improved efficacy of chemotherapy,
only a fraction of patients respond to it [6,7]. Furthermore,
there are a lack of accurate markers for predicting tumor
response that can be used to identify those patients who
might safely discontinue prolonged treatment and those
who should resume chemotherapy quickly. Such markers
could reduce the use of chemotherapy in nonresponsive
patients, reducing unnecessary costs and toxicity [8,9].
Circulating tumor cells (CTCs) have been detected in the
peripheral blood of patients with various cancers [10-12].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prognostic and predictive markers in patients with
breast or prostate cancer [10,12]. However, the clin-
ical significance of CTCs in CRC patients treated with
chemotherapy and targeted agents has not yet been
confirmed consistently, and whether CTCs can be used as
a predictive marker for response to chemotherapy is
controversial.
The aim of our study was to use a meta-analysis
to comprehensively summarize the prognostic and
predictive significance of CTCs in evaluating the response
to chemotherapy in CRC patients.
Methods
Search strategy
PubMed, Embase, the Science Citation Index, Cochrane
Database and the Ovid Database were systematically
searched for studies of the prognostic and predictive
significance of CTCs in CRC patients treated with
chemotherapy, with no restrictions on language, place
of publication or date of publication (up to April, 2014).
The reference lists of the retrieved studies and reviews
were also perused manually to check for potentially
relevant studies. The main search terms used were
“circulating tumor cells”, “isolated tumor cells”, “occult
tumor cells”, “peripheral blood”, “colorectal cancer”,
“colon cancer”, “rectal cancer”, “gastrointestinal cancer”,
“chemotherapy” and “targeted treatment/agent”.
Study eligibility criteria
Studies were considered eligible if they met all of the
following criteria: (1) all enrolled patients (>20) were
diagnosed with CRC; (2) prognostic and predictive
significance of CTCs in patients treated with chemotherapy
was assessed with at least one of the outcome measures of
interest reported in the study or calculated from the
published data; (3) tumor response to chemotherapy
was assessed according to the Response Evaluation
Criteria In Solid Tumors (RECIST) guidelines (complete
response [CR], partial response [PR], stable disease [SD]
or progressive disease [PD]) [13]; and (4) the samples were
collected from peripheral blood. When several studies
were based on the same patient population, only the most
informative study was included.
Data extraction and quality assessment
Two reviewers (X. Z. Huang and P. Gao) independently
extracted data from eligible studies. The following informa-
tion was extracted: first author, year of publication,
population characteristics, chemotherapy, sampling times
(before the initiation of surgery and chemotherapy
[“baseline”] or after the initiation of chemotherapy
[“during chemotherapy”]), detection method, rate of CTC
positivity, follow-up period, cut-off point, prognostic values(OS and PFS) and objective response to chemotherapy
(CR, PR, SD or PD).
The quality of the included studies was assessed with
the Newcastle-Ottawa Scale (NOS) criteria for cohort
studies [14]. A funnel plot was used to assess publication
bias. Any disagreements on data extraction and quality
assessment of the included studies were resolved
through comprehensive discussion. All written informed
consents for participants have been described and
obtained by the studies that were included in our
meta-analysis.
Statistical analysis
Our meta-analysis was performed with Stata software,
version 12.0 (2011) (Stata Corp, College Station, TX,
USA), in accordance with the recommendations of the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) [15]. The odds ratios (ORs),
risk ratios (RRs) and hazard ratios (HRs) were regarded as
effect measures for summarizing prognosis and objective
response to chemotherapy. If the HR and its 95% confi-
dence interval (95% CI) were not provided directly, they
were calculated from the available data using the method
reported by Jayne F. Tierney [16].
To retain maximum information, if one study reported
several results separately for different blood samples
collected during chemotherapy, we combined multiple
effect values into a pooled estimate for further meta-
analysis. All relevant studies were included in the overall
analysis. A subgroup analysis was performed simultan-
eously based on the sampling time (baseline or during
chemotherapy) and CTC detection method. We assessed
the correlation between the CTC level and the response
to chemotherapy, assuming radiographic imaging to be
the gold standard, and in this way, determined the
sensitivity and specificity of CTC-high status in predicting
the response rate (CR + PR) or the disease control rate
(CR + PR + SD). Sensitivity, specificity, positive predictive
value, negative predictive value and area under the
receiver operating characteristic curve [ROC] were
calculated using the binomial rendition of the bivariate
mixed-effects regression model [17,18].
A p value <0.05 was considered statistically significant
and CI was set at 95%. In addition to the diagnostic
accuracy test, the remaining analyses used a random-
effects model, because it provided more conservative
estimates and was more tailored to multicenter studies in
which heterogeneity was usually present [19]. Heterogeneity
among studies was evaluated using the Cochran Q test
and I2 statistic [20]. Potential sources of heterogeneity
were explored using a meta-regression analysis and
Galbraith plot. To maintain the accuracy of the results of
the meta-regression, the analysis was only conducted
when the number of studies was greater than 10 [21,22].
Huang et al. BMC Cancer 2014, 14:976 Page 3 of 15
http://www.biomedcentral.com/1471-2407/14/976We used Egger’s and Begg’s tests to investigate publication
bias [23,24] and conducted trim-and-fill analysis to
evaluate the effect of publication bias [25]. A sensitivity ana-
lysis was conducted to assess the quality and consistency of
results using the leave-one-out approach.
Ethics statement
The study did not violate the local regulations, and was
approved by the Research Ethics Committee of China
Medical University, China.
Results
Baseline characteristics of the included studies
Seven hundred and twelve relevant studies were initially
identified in the literature search. After screening titles
and abstracts, 650 studies were excluded and 62 potential
studies were reviewed further. An additional 49 studies
were then excluded because they were redundant studies
or lacked the outcomes of interest. Finally, 13 studies were
identified as eligible for inclusion in the meta-analysis
(Figure 1).
The 13 studies included 2388 eligible CRC patients
(median sample size: 76 [38–735]; mean: 184). The studies
were conducted in Asia, Europe, Oceania and North
America, and were published between 2008 and 2014.
In terms of sampling time, seven studies assessed the
significance of CTCs detection at baseline and during
chemotherapy separately [11,26-31]: one study assessed
the significance of CTCs combined at both time points
[32], three assessed the significance of CTC detection onlyFigure 1 Selection of studies. Flow chart showing the selection
process for the included studies.at baseline [33-35], one study assessed the significance of
CTC detection only during chemotherapy [36] and one
study did not report sampling times [37]. Six studies
showed the relationship between clinical outcomes and
CTC changes during chemotherapy [11,26-29,32].
Nine of the 13 studies only enrolled eligible patients
with metastatic CRC (mCRC) [11,26,28-31,33,34,37].
Table 1 summarizes the main baseline characteristics
and study design variables. The quality of the included
studies was evaluated with the NOS and is summarized
in Table 2.
Correlation of CTCs with the objective response to
chemotherapy
Our meta-analysis suggested that the disease control
rate was significantly higher in CRC patients with
CTC-low compared with CTC-high (RR = 1.354, 95%
CI [1.002–1.830], p = 0.048), and patients with CTC-low
tended to have a favorable response rate, although
statistical significance was not reached (RR = 1.740,
95% CI [0.878–3.447], p = 0.113) (Figure 2). A similar
tendency was obtained in the subgroup analysis based
on sampling time: baseline (response rate: RR = 1.258,
95% CI [0.990–1.598], p = 0.060; disease control rate:
RR = 1.375, 95% CI [0.961–1.967], p = 0.082) and during
chemotherapy (response rate: RR = 2.315, 95% CI
[1.242–4.316], p = 0.008; disease control rate: RR = 1.535,
95% CI [1.170–2.016], p = 0.002). After excluding studies
containing stage II–III patients, the pooled results of the
subgroup analysis of mCRC patients were still significant
(disease control rate: RR = 1.354, 95% CI [1.065–1.721],
p = 0.013). We also conducted a pooled analysis using the
CellSearch system method, a standardized semiautomated
quantification method system approved by the U.S.
Food and Drug Administration, with similar results. These
estimated results for the response to chemotherapy are
summarized in Table 3.
For CTCs detected at baseline, sensitivity and specificity
of CTC-high for imaging-based disease progression
were 52.0% (95% CI [21.5–81.1%]) and 68.7% (95% CI
[57.4–78.2%]), respectively. Positive and negative predictive
values were 40.4% (95% CI [11.7–77.6%]) and 77.3% (95%
CI [46.1–93.1%]), respectively, and the area under the
ROC curve was 0.68 (95% CI [0.10–0.98]). Sensitivity
and specificity of the CTCs detected during chemotherapy
were 50.0% (95% CI [19.6–80.4%]) and 89.5% (95%
CI [79.3–95.0%]), respectively. Positive and negative
predictive values were 40.9% (95% CI [22.7–62.1%])
and 90.6% (95% CI [80.1–95.8%]), respectively, and the
area under the ROC curve was 0.86 (95% CI [0.15–1.00]).
For the imaging-based nonresponse (SD + PD), sensitivity
and specificity of CTCs detected at baseline and during
chemotherapy were 30.2% (95% CI [10.1–62.5%]) and
91.1% (95% CI [75.6–97.1%]), respectively. Positive and
Table 1 Baseline characteristics and design variables of the included studies
Reference Number
(M/F)
C/R/RS ST CRT before
and after ST
Age mean ± SD/
median (range)







Barbazan 2014 [30] 50(37/13) 34/14 baseline NO/YES 64.5 ± 10.3; 31-84 RT-PCR 13/50 0-40 mCRC PFS,OS(3) PFS,OS, NR







Kuboki 2013 [34] 63(34/29) 41/22/0 baseline NO/YES 61(33–81) Cellsearch 19/63 median:8.7 mCRC PFS,OS(3) PFS,OS,
RECIST
NR
Lu 2013 [36] 90(51/39) 90/0/0 1,4 W YES/YES 63.1 ± 12.9 membrane-array 21/90 36(18–61) III
stage
PFS,OS(3) PFS,OS YES
Iinuma(1) 2013 [35] Training:
420(224/196)
NR baseline NO/YES 66.0 ± 12.4 RT-PCR 57/150 36.9 ± 19.5 Dukes’ C PFS,OS(3) PFS,OS YES
Iinuma(2) 2013 [35] Validation:
315(175/140)
NR baseline NO/YES 67.5 ± 11.8 RT-PCR 35/97 37.1 ± 18.1 Dukes’ C PFS,OS(3) PFS,OS YES
Sastre 2012 [26] 180(118/62) 121/40/19 baseline NO/YES 65(40–82) Cellsearch 85/180 29(0–53.2) mCRC PFS,OS(3) PFS,OS,
RECIST
123YES










33 NR 1-4 W;
5-8 W;
9-12 W
YES/YES NR RT-PCR 18/33;
19/33;
17/33
NR NR NR RECIST NR
Matsusaka 2011 [28] 64(31/33) 36/28 baseline NO/YES 59(18–72) Cellsearch 12/64 0-36 mCRC PFS(3);OS(10) PFS,OS,
RECIST
NR
/ NR 2 W;
8-12 W
YES/YES NR Cellsearch 7/63;
4/60
NR mCRC PFS(3);OS(10) PFS,OS,
RECIST
NR
Konigsberg 2010 [33] 38(23/15) NR mixed NO/YES 65(44–82) ICC 23/38 11.7(8.4-14.9) mCRC PFS,OS(3) PFS,OS,
RECIST
NR
Yalcin 2010 [32] 93(50/43) NR mixed part
NO/YES




Tol 2010 [29] 467(284/183) 225/122/120 baseline NO/YES 63(27–83) Cellsearch 129/451 16.8 mCRC PFS,OS(3) PFS,OS,
RECIST
NO
/ NR 1-2 W YES/YES NR Cellsearch 21/368 NR mCRC PFS,OS(3) PFS,OS,
RECIST
NR
/ NR 3-5 W;
6-12 W;
13-20 W
YES/YES NR Cellsearch 17/320;
18/336;
16/254
NR mCRC PFS,OS(3) PFS,OS,
RECIST
NR
Yen 2009 [37] 76(44/32) 55/21 NR NR 64(39–83) membrane-
array




















Table 1 Baseline characteristics and design variables of the included studies (Continued)
Cohen 2008 [11] 430(238/192) 292/71/66 baseline NO/YES 64(22–92) Cellsearch 107/413 12.6 ± 6.5/11.0(0.8-30.0) mCRC PFS,OS(11) PFS,OS,
RECIST
NR
/ NR 3-5 W YES/YES NR Cellsearch 38/320 NR mCRC PFS,OS(11) PFS,OS,
RECIST
NR
/ NR 1-2 W;
6-12 W;
13-20 W
YES/YES NR Cellsearch 41/357;
25/310;
21/193
NR mCRC PFS,OS(11) PFS,OS,
RECIST
NR
Staritz 2004 [31] 42 NR baseline NO/YES NR RT-PCR 19/41 13.7(1.9-25.4) mCRC OS(10) OS NR
1 day YES/YES NR RT-PCR 23/40 13.7(1.9-25.4) mCRC OS(10) OS NR
NOTE, M/F: Male/female; C/R/RS: Colon/rectum/rectosigmoid; ST: Sample time; CRT: Chemoradiotherapy before and after sampling time; SD: Standard deviation; Rate (+): Rate of CTCs positive patients, n/N (%); OM:
Outcome measured; Mixed: samples without separation based on sampling time; mCRC: metastatic colorectal cancer; OS: Overall survival; PFS: Progression-free survival; HR: Hazard Ratio; RECIST: Response evaluation


















NOTE: Weights are from random effects analysis































NOTE: Weights are from random effects analysis





















Figure 2 Risk ratios (RR) summary for correlation of CTCs and tumor response. A: The risk ratio (RR) was summarized for the correlation of
tumor response rate with CTCs detection. B: The RR was summarized for the correlation of tumor disease control rate with CTCs detection.
Table 2 The assessment of the risk of bias in each cohort study using the Newcastle-Ottawa scale
Study Selection (0–4) Comparability (0–2) Outcome (0–3) Total
REC SNEC AE DO SC AF AO FU AFU
Barbazan 2014 [30] 0 1 1 1 0 0 1 1 0 5
Kuboki 2013 [34] 0 1 1 1 0 0 1 0 0 4
Lu 2013 [36] 1 1 1 1 0 0 1 1 1 7
Iinuma 2013 [35] 1 1 1 1 0 0 1 1 0 6
Sastre 2012 [26] 1 1 1 1 0 0 1 1 0 6
de Albuquerque 2012 [27] 0 1 1 1 0 0 1 0 1 5
Matsusaka 2011 [28] 0 1 1 1 1 0 1 1 0 6
Konigsberg 2010 [33] 0 1 1 1 0 0 1 0 0 4
Yalcin 2010 [32] 0 1 1 1 0 0 1 0 0 4
Tol 2010 [29] 1 1 1 1 0 0 1 1 0 6
Yen 2009 [37] 1 1 1 1 0 0 1 1 0 6
Cohen2008 [11] 0 1 1 1 0 0 1 1 0 5
Staritz 2004 [31] 0 1 1 1 0 0 1 0 1 5
NOTE. REC: representativeness of the exposed cohort; SNEC: selection of the non-exposed cohort; AE: ascertainment of exposure; DO: demonstration that outcome
of interest was not present at start of study; SC: study controls for age, sex; AF: study controls for any additional factors (chemoradiotherapy, curative resection);
AO: assessment of outcome; FU: follow-up long enough (36 Months) for outcomes to occur; AFU: adequacy of follow-up of cohorts (≥90%). ‘1’ means that the
study is satisfied the item, and ‘0’ means the opposite situation.
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Table 3 Detailed results of subgroup analyses for prognostic and predictive significance
Sample time Method CellSearch
Any Baseline During-chemotherapy CellSearch No-Cellsearch Baseline During- chemotherapy
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ii¶: included patients with metastatic colorectal cancer.
iiiN = 1: only one eligible study without pooled analysis.
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http://www.biomedcentral.com/1471-2407/14/976negative predictive values were 79.4% (95% CI [69.1–86.9%])
and 50.4% (95% CI [23.9–76.7%]), respectively, and the
area under the ROC curve was 0.77 (95% CI [0.73–0.81]).
We analyzed three studies that suggested that CTC
levels during chemotherapy could provide additional
predictive information on survival outcomes when added
to radiographic imaging [11,29,30]. The OS of CTC-low
patients with disease control (median time: 21.694 months,
95% CI [18.871–24.517]) was significantly longer than that
of CTC-low patients with PD (median time: 7.943 months,
95% CI [5.680–10.206]), CTC-high patients with dis-
ease control (median time: 9.613 months, 95% CI
[6.090–13.137]), and CTC-high patients with PD (median
time: 3.327 months, 95% CI [2.398–4.257]). Differences in
median OS between CTC-low patients with disease control
and patients in the other three groups were statistically
significant (p < 0.0001 for all three comparisons) (Figure 3).Conversion of CTC levels and prognosis
When we compared CTC levels of samples collected at
baseline with those collected during chemotherapy, our
results suggested that CRC patients who converted
from CTC-low to CTC-high or who were persistently
CTC-high during treatment had an unfavorable progressive
disease compared with those CRC patients who con-
verted from CTC-high to CTC-low (OR = 27.088, 95%
CI [4.960–147.919], p < 0.001) (Figure 4). Therefore, it
was understandable that CRC patients who became
CTC-high or were persistently CTC-high were signifi-




Group 1 vs Group 2
Tol
Cohen
Subtotal  (I−squared = 26.7%, p = 0.243)




Subtotal  (I−squared = 0.0%, p = 0.839)




Subtotal  (I−squared = 0.0%, p = 0.449)
Study
0−23.2
Figure 3 Results for the meta-analysis of overall survival (OS) time. Th
and radiographic imaging, Group 1: patients with CTC-low during chemoth
chemotherapy and progression disease (PD), Group 3: patients with CTC-hi
CTC-high during chemotherapy and PD.[1.105–3.969], p = 0.023) and a poor OS (HR = 3.604, 95%
CI [2.096–6.197], p < 0.001). These results are summarized
in Table 3.Impact of CTCs on survival outcomes (PFS and OS)
HRs for PFS were available in eleven studies. The estimated
pooled HRs indicated that CTC-high status was associated
with a significantly decreased PFS (HR = 2.500, 95%
CI [1.746–3.580], p < 0.001). Eleven studies provided
HRs on OS and the pooled results indicated that
CRC patients in the CTC-high group were significantly
associated with a poor OS (HR = 2.856, 95% CI
[1.959–4.164], p < 0.001; Figure 5). The pooled results
of the subgroup analysis of mCRC patients were similar to
the results of the overall analysis when we excluded the
four studies containing stage II–III patients (PFS: HR =
2.237, 95% CI [1.485–3.370], p < 0.001; OS: HR = 2.642,
95% CI [1.716–4.067], p < 0.001). Interestingly, for the
stage II–III subpopulation, CTCs were still a significant
poor prognostic factor for survival: (PFS: HR = 3.226,
95% CI [2.193–4.745], p < 0.001; OS: HR = 3.735, 95%
CI [1.710–8.158], p = 0.001). The estimated HRs for
PFS and OS were similar in the subgroup analysis of
the studies in which most mCRC patients underwent
surgery (Table 3).
As shown in the subgroup analysis based on sampling
time, CTCs were confirmed as a significant prognostic
factor for survival: at baseline (PFS: HR = 1.853, 95%
CI [1.405–2.445], p < 0.001; OS: HR = 2.356, 95% CI

























e differences in median OS time based on the combination of CTCs
erapy and disease control, Group 2: patients with CTC-low during
gh during chemotherapy and disease control, Group 4: patients with
Figure 4 The results for the relationship between CTCs conversion and prognosis. A: The estimated odds ratio (OR) was summarized for
the correlation of disease control rate with CTCs conversion. B: The estimated hazard ratio (HR) was summarized for progression-free survival (PFS) with
CTCs conversion. C: The estimated HR was summarized for overall survival (OS) with CTCs conversion.
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http://www.biomedcentral.com/1471-2407/14/976(PFS: HR = 2.386, 95% CI [1.454–3.917] p = 0.001; OS:
HR = 3.292, 95% CI [1.611–6.726], p = 0.001). A simi-
lar trend was observed in the pooled analysis using
the CellSearch system method (PFS: HR = 1.769, 95%
CI [1.180–2.651], p = 0.006; OS: HR = 2.452, 95% CI
[1.484–4.050], p < 0.001).
Evaluation of heterogeneity and publication bias
Neither the direction nor the magnitude of the estimated
pooled results was obviously affected when each study
was removed in the sensitivity analysis, indicating that no
single study dominated our results (Additional file 1). The
Galbraith plot showed that the study by Matsusaka et al.
[28] contributed substantial heterogeneity to our
meta-analysis. Exclusion of the study by Matsusaka et al.[28] could increase statistical power and reduce hetero-
geneity in the overall and subgroup analyses (Table 3).
Begg’s and Egger’s tests were used to examine publication
bias (Additional file 2). No significant publication bias was
found in the results, except in the HRs for PFS. The
trim-and-fill analysis indicated that there might be
three unpublished or missing studies existing in the
meta-analysis on PFS and the three studies might have an
effect on the outcome, and the relationship of CTCs and
PFS was still statistically significant if the three stud-
ies were published (HR = 2.069, 95% CI [1.505–2.842],
p < 0.001). To explore the potential sources of heterogen-
eity, we conducted a meta-regression that considered the
covariates of year, sample size, sampling time and detection
method. In a univariate analysis, the explanatory variable
NOTE: Weights are from random effects analysis
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Figure 5 Estimated hazard ratios (HR) summary for PFS (A) and OS (B). A: The estimated hazard ratio (HR) was summarized for progression-free
survival with CTCs detection. B: The estimated HR was summarized for overall survival with CTCs detection.
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was detection method (PFS: coefficient = 0.415, standard
error = 0.104, p = 0.001; OS: coefficient = 0.341, standard
error = 0.157, p = 0.046), while sampling time was also
another potential source of heterogeneity (Additional file 3).
Discussion
In recent years, standard combined chemotherapy has
been widely used for patients with operable or inoperable
CRC, and the clinical prognosis of CRC patients has
improved [3]. Unfortunately, chemotherapy does not always
translate into survival benefits, and unnecessary toxicity
can affect patient quality of life [38]. To date, there are no
available predictive markers to resolve this problem. Recent
studies have assessed whether CTCs can be used as a
predictive marker for the response to chemotherapy, but
the predictive role of CTCs is still controversial [28].To our knowledge, this is the first meta-analysis to
assess the prognostic and predictive value of CTCs in CRC
patients treated with chemotherapy. Our meta-analysis
indicated that CTCs detected at baseline and during
chemotherapy was significantly associated with prognosis
(PFS and OS) in CRC patients. Moreover, for the response
to chemotherapy, CTCs detected during chemotherapy
were significantly associated with response rate and
disease control rate (p < 0.05), and CTCs detected at
baseline trended towards an unfavorable response rate
and disease control rate, although statistical significance
was not reached. A sensitivity analysis, performed by
omitting each study individually, confirmed the stability of
our results. We also performed a pooled analysis to assess
the clinical value of CTCs in mCRC patients only and in
stage-II–III patients only, with similar results. These
results were consistent with a previous meta-analysis,
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outcomes [39].
Increasing attention has been paid to the use of CTCs
in predicting the efficacy of chemotherapy. Cristofanilli
et al. reported that CTC levels could predict the efficacy
of chemotherapy in patients with breast cancer earlier
than traditional diagnostic methods (at 3–4 weeks versus
9–12 weeks, respectively) [10]. The time at which
CTCs were first sampled (range: 1–5 weeks) was generally
earlier than the time at which radiographic imaging was
performed to assess tumor response (range: 6–25 weeks)
in the included studies, when the authors assessed
the correlation between CTCs and the response to
chemotherapy.
Our results also suggested that the presence of CTCs
before and during chemotherapy could be used as an
early predictive marker of tumor response in CRC
patients treated with chemotherapy. At 1–5 weeks after
the initiation of chemotherapy, CTC-high patients had
approximately 1.5 times the risk of radiographic PD than
CTC-low patients. This could provide earlier opportunities
for intervention or for the adjustment of chemotherapy by
changing the chemotherapeutic regimen, intensity and/or
period. Therefore, CTCs could be very valuable in resolving
the problem in which an inefficient chemotherapy regimen
is administered to a CRC patient for a prolonged period or
a potentially effective chemotherapy regimen is interrupted
prematurely.
However, we noted that the sensitivity and specificity
of CTCs in predicting the tumor response determined
by radiographic imaging were slightly limited. The most
plausible explanation may be that the effects of targeted
chemotherapy within a few CRC patients do not always
translate into a change in tumor size. For example,
angiogenesis inhibitors and antivascular therapies (i.e.,
bevacizumab and sorafenib) could cause necrosis and
cavitation without tumor shrinkage [40,41]. This was
consistent with the imprecise correlation between the
objective response and the survival outcome [42].
Indeed, several studies included in our analysis evaluated
these targeted agents (i.e., bevacizumab or cetuximab) in
CRC patients. Therefore, CTCs could provide additional
relevant information on the efficacy of chemotherapy,
especially in the context of the disadvantages of radio-
graphic imaging. Limitations of CTC detection methods
may also explain the limited sensitivity and specificity of
CTCs in predicting the tumor response (i.e., moderate
sensitivity of immunological techniques and low specificity
of the RT-PCR technique). Therefore, the integration of
CTC detection at baseline and during chemotherapy
(or at different “during-chemotherapy” times) may more
accurately predict the tumor response. Further studies are
required to investigate ways to improve the accuracy of
CTCs in predicting the response to chemotherapy andwhether a combined analysis of CTCs and radiographic
imaging will be more accurate in assessing the prognosis
in CRC patients.
Interestingly, we analyzed the effect of CTCs as a
predictive biomarker according to different sampling
times (at baseline, 6–12 weeks, 6–12 weeks and 13–20
weeks after the initiation of chemotherapy) and the results
suggested that the prognostic and predictive significance
of CTCs was relevant to CTC sampling time. This finding
concurred with the results of the meta-regression analysis
suggesting that sampling time was an important factor.
This may occur because of the interaction between
CTCs and chemotherapeutic drugs. Furthermore, tumor
proliferative activity and response to chemotherapeutic
agents may also impact CTC status during chemotherapy
[43]. However, the underlying reasons for the different
effects of CTCs detected before and during chemotherapy
were unclear and will need to be investigated in future
studies. In the clinic, the relevance of CTCs as a predictive
biomarker may have maximal value in a pre-treatment
setting. Meanwhile, CTCs detected during chemotherapy
may indicate that the drug given was not working and
may not necessarily predict benefit from a higher dose
(which would be toxic) or a different drug.
Recent studies have also demonstrated that fluctuations
in CTC levels before and during chemotherapy were closely
associated with the tumor response to chemotherapy and
prognosis, and should be of value in individualizing chemo-
therapy [44]. Our meta-analysis indicated that there was a
more pronounced association between the disease control
rate/prognosis and changes in CTC levels than between the
disease control rate/prognosis and CTC levels at baseline
or during chemotherapy alone (Table 3).
This finding was supported by five of the included stud-
ies, which provided prognoses or responses to chemother-
apy according to changes in CTC levels [11,26,27,29,32].
The main reason for this result may be that changes in
CTC levels better reflect chemotherapeutic sensitivity and
tumor proliferative activity [43]. This finding suggested
that fluctuations in CTC levels compensated for the limited
sensitivity and specificity of CTCs in predicting the
tumor response. Therefore, our results indicated that
“real-time” CTC levels detected at different times during
chemotherapy, combined with radiographic imaging, should
be helpful in guiding individual therapeutic decisions.
Heterogeneity was observed among the studies in our
meta-analysis. In particular, the study by Matsusaka et al.
[28] contributed substantial heterogeneity to our meta-
analysis. A possible reason was that the patients included
had better Eastern Cooperative Oncology Group (ECOG)
performance scores (0–1 versus 0–2, respectively) and a
younger median age than those in the other included
studies. Excluding the study by Matsusaka et al. [28],
heterogeneity could be decreased but not eliminated.
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and detection method were sources of heterogeneity.
Indeed, heterogeneity was reduced in the subgroup analysis
based on sampling time and detection method, confirming
the results of our meta-regression analysis (Table 3).
Heterogeneity could have also been caused by differences
in patient characteristics (i.e., age, sex and race), biological
differences between colon cancer and rectal cancer,
and differences in the chemotherapy strategies used.
Furthermore, cytogenetically heterogeneous CTC pop-
ulations could have contributed to the heterogeneity
among the studies [45]. The studies included were all
nonrandomized trials and cohort studies; therefore,
differences in experimental design may have also given
rise to heterogeneity.
Several limitations of this meta-analysis must be noted.
First, our meta-analysis was not conclusive regarding
when CTCs should be evaluated after the initiation of
chemotherapy and what levels of CTCs would be useful
for clinical prognostication. Second, as a retrospective
study, our meta-analysis was based on published data
from the studies included. Several studies did not
provide HRs directly and we estimated them from the
published data [11,27,28]. Third, although the meta-
regression showed that sampling time and detection
method were the sources of heterogeneity, heterogeneity
could not be eliminated because of other factors mentioned
above (i.e., patient characteristics, chemotherapy strategies
and heterogeneous CTC populations). Therefore, the
prognostic power of CTCs must be confirmed with
large-scale multicenter studies in homogeneous patients.
Fourth, we pooled the studies without separating them into
their subcohorts of patients with colon cancer and patients
with rectal cancer, because no study provided these data
separately. Furthermore, most of the studies included did
not comprehensively report patient status regarding surgery
or neoadjuvant chemoradiotherapy, thus we could not
conduct an in-depth subgroup analysis that adjusted for
these confounding factors. The limited number of studies
that were included in the subgroup and sensitivity analyses
would have also influenced the statistical power of our
results. Despite these limitations, our meta-analysis is the
first study to assess the prognostic and predictive value of
CTCs in CRC patients treated with chemotherapy.
Conclusions
Our meta-analysis indicates that CTCs could be useful as a
surrogate marker for the response to chemotherapy
providing additional prognostic information to tumor
radiographic imaging. CTCs were also associated with
the prognosis of CRC patients treated with chemotherapy.
As a “liquid biopsy”, CTC detection is a less invasive way
to evaluate the prognosis and response to chemotherapy
of CRC patients than a biopsy of the primary tumor.Further high-quality, well-designed, large-scale multicenter
studies are required to explore whether an individualized
therapeutic decision based on CTC levels would improve
the prognosis of CRC patients.
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